Plain language summary
======================

**Why was the study done?** For the newly diagnosed stage IV melanoma patients, the necessity and effect of primary tumor surgery has never been discussed.

**What did the researchers do and find?** We assessed the effect of primary tumor surgery on survival using Cox proportional hazard regression modeling and stratified propensity score matching as well, based on data from the Surveillance, Epidemiology, and End Results (SEER) database. The results show that primary tumor surgery is significantly associated with better patients' survival.

**What do these results mean?** This study challenges the conventional view and may fill in the gap of the relevant knowledge in the guideline.

Introduction
============

Malignant melanoma accounts for the vast majority of skin cancer deaths in the USA.[@b1-cmar-11-339] For melanoma patients with distant metastasis, the overall survival (OS) was only 9 months before 2009 and has improved to about 10--17 months in the recent decade. [@b2-cmar-11-339],[@b6-cmar-11-339] Common treatment options for metastatic melanoma comprise surgery, systemic therapy and radiotherapy. In spite of the fact that the surgical resection of metastases is suggested to be conducive to survival, complete resection of metastases is feasible in only a small proportion of carefully selected patients with metastatic melanoma.[@b3-cmar-11-339]--[@b5-cmar-11-339] As systematic treatment represented by immune checkpoint inhibitors and targeted therapy has been becoming more important in the treatment of metastatic melanoma, the status of surgery has diminished in the last decade.[@b6-cmar-11-339]--[@b8-cmar-11-339]

The primary tumor surgery is an effective means to treat or even potentially cure early-stage melanoma.[@b9-cmar-11-339] However, for the melanoma patients with the primary tumor and metastatic disease concurrently occurring at the time of diagnosis (newly diagnosed metastatic patients), the necessity and effect of primary tumor surgery has never been discussed. The benefit of primary tumor surgery in improving survival that had been observed in other metastatic malignancies, such as breast cancer,[@b10-cmar-11-339]--[@b14-cmar-11-339] colorectal cancer,[@b15-cmar-11-339]--[@b17-cmar-11-339] gastric cancer,[@b18-cmar-11-339]--[@b20-cmar-11-339] renal cell cancer[@b21-cmar-11-339] and so on, made us wonder whether there would be a similar effect on metastatic melanoma. The Surveillance, Epidemiology, and End Results (SEER) database provides diagnosis, first-course treatment (including primary tumor surgery) and prognostic information of a considerable number of tumor patients.[@b22-cmar-11-339] Besides, as SEER only provides information on initial diagnosis but not information of disease recurrence, all its cases are newly diagnosed, meaning that all stage IV patients from the SEER are in stage IV at new diagnosis. This makes it possible for us to study the impact of primary tumor surgery on the survival of the newly diagnosed stage IV patients.

The objective of this study was to assess the prognostic value of primary tumor surgery in metastatic melanoma patients after minimizing a potential case selection bias by using propensity score-matching analysis, based on data from the SEER database.

Patients and methods
====================

Data source and patient selection
---------------------------------

A query of the SEER registry using SEER\*Stat 8.3.5 was performed to identify all stage IV patients diagnosed as malignant melanoma (ICD-O-3/WHO-2008 recode of "melanoma of the skin") between the years 2004 and 2015, based on the 1973--2015 SEER research incidence data (November 2017 submission).[@b23-cmar-11-339] The information on surgery of primary tumor and metastatic sites, survival time, cause of death and other characteristics was identified. The cases with unknown surgical status or survival time and those with secondary malignancies at diagnosis were removed from the analysis. The characteristics of patients and tumor included time of diagnosis, age, sex, race, marital status, primary tumor site, histologic type, TNM stage and ulceration. Primary sites of melanoma were stratified into face/head/neck, trunk, limbs and other/unknown sites. Histologic types were stratified into nodular melanoma, superficial spreading melanoma, spindle cell melanoma and others/unknown types. The T, N and M stages were defined based on the American Joint Committee on Cancer TNM classification system for melanoma (sixth edition, 2002).

Statistical analyses
--------------------

Kaplan--Meier curves were used to compare both OS and melanoma-specific survival (MSS, ie, death caused by cutaneous melanoma) in surgery and non-surgery groups. To further analyze the prognostic value of primary tumor surgery, multivariate Cox proportional hazard models were also used identify the factors associated to patients' survival. Besides, we conducted stratified analysis to estimate the effect of primary tumor surgery before and after the year 2011 (2004--2010 and 2011--2015), respectively.

Propensity score matching
-------------------------

As the included patients were not randomized in this retrospective study, the unbalanced baseline characteristics may lead to selection bias, and hence influence the decision to treat with primary tumor surgery.[@b24-cmar-11-339] To reduce this impact, a matched case--control analysis was conducted by using propensity score matching. By using the propensity scores estimated according to the baseline covariates listed in [Table 1](#t1-cmar-11-339){ref-type="table"}, a matched dataset was created. Patients who received primary tumor surgery were matched to patients who did not receive the same, based on the calculated propensity scores with an algorithm of the nearest-neighbor 1:1 matching.[@b25-cmar-11-339]

Data analysis was performed using SPSS Statistics 20.0 (IBM Corporation, Armonk, NY, USA). The categorical variables are presented as percentages and numbers, and comparisons are made using χ^2^ tests. Log-rank tests were used to compare the difference in survival between patients in different groups. All tests were two-sided, and a *P*-value of \<0.05 was considered statistically significant.

Results
=======

Eight thousand three hundred and forty-one patients who had been diagnosed with primary melanoma and metastatic disease at the same time were included in this analysis, of which 2,554 (30.6%) received surgery of the primary tumor and 2.1% received metastasectomy ([Table 1](#t1-cmar-11-339){ref-type="table"}). The median OS and MSS of all patients were 8.0 months (95% CI 7.7--8.3 months) and 9.0 months (95% CI 8.5--9.5 months), respectively.

On univariate analysis of the unmatched cohort, patients receiving surgery of the primary tumor had both better median OS (13 vs 6 months, *P*\<0.001) and median MSS (15 vs 7 months, *P*\<0.001), compared with those who did not receive the same ([Figure 1](#f1-cmar-11-339){ref-type="fig"}). Besides, this trend occurred in both periods of 2009--2010 (OS: 12 vs 5 months; MSS: 13 vs 6 months) and 2011--2015 (OS: 14 vs 6 months; MSS: 22 vs 9 months), with all *P*-values being \<0.001 (data not shown). On multivariable Cox regression analysis, undergoing primary tumor surgery was an independent protective factor of OS (HR =0.617, 95% CI 0.565--0.674; *P*\<0.001) and MSS (HR =0.599, 95% CI 0.537--0.668; *P*\<0.001), as shown in [Table 2](#t2-cmar-11-339){ref-type="table"}. The other protective factors of OS included later years of diagnosis (2011--2015; HR =0.837, 95% CI 0.790--0.886; *P*\<0.001), married status (HR =0.770, 95% CI 0.730--0.813; *P*\<0.001) and metastasectomy (HR =0.466, 95% CI 0.381--0.570; *P*\<0.001), as shown in [Table 2](#t2-cmar-11-339){ref-type="table"}. The risk factors of OS included older age, sex of male, tumor location of trunk, historical type of nodular melanoma and higher T, N and M stages. The protective and risk factors of MSS were similar to those of OS.

Several factors such as age, tumor site, histologic type, TNM stage and so on were significantly associated with the rate of primary tumor surgery in unmatched cohort. To further corroborate the benefits of surgery found in univariate and multivariate analyses, we performed a propensity score matching to optimally adjust for the selection bias between the two groups ([Table 1](#t1-cmar-11-339){ref-type="table"}). As in the unmatched cohort, surgery of primary tumor was also associated with better OS (13 vs 6 months, *P*\<0.001) and MSS (18 vs 6 months, *P*\<0.001) in the matched cohort ([Figure 2](#f2-cmar-11-339){ref-type="fig"}).

Discussion
==========

Metastatic melanoma has been an incurable disease in spite of the improvement in survival largely attributed to advances in systemic treatment options over the last decade, while the role of the primary tumor surgery in this setting is still ambiguous due to the lack of relevant research. To the best of our knowledge, this is the first study to evaluate the impact of primary tumor surgery on metastatic melanoma. Moreover, as the SEER database encompasses 28% of the US population,[@b1-cmar-11-339] our data are, to some extent, generalized and reflective of the population experience.

Historically, the surgery in metastatic patients was generally referring to the surgery for metastatic sites (ie, the metastasectomy), which was performed for palliation or potentially cure.[@b5-cmar-11-339] The National Comprehensive Cancer Network guideline[@b26-cmar-11-339] recommends feasible metastasectomy in the patients with stage IV melanoma, but it does not describe whether primary tumor surgery should be performed in this population. The lack of attention to the primary tumor surgery in metastatic melanoma may be partly ascribed to the fact that most metastatic diseases occur when the primary tumor has already been removed in earlier treatment. Importantly, all stage IV patients from SEER are newly diagnosed cases, whose primary tumors and metastases coexist when diagnosed as cancer. In other words, their primary tumor has not been removed yet. This may explain why the rate of primary tumor surgery in this study was as high as 31%, although the reasons for this or the guidelines followed by the US clinicians in the practice are unclear as far as we know. More importantly, both our results of Cox proportional hazard regression and analyses after propensity score matching demonstrated significant benefits of primary tumor surgery to OS and cancer-specific survival regardless of the patient, tumor and treatment characteristics. Although the results need to be further validated, they should call our attention to the benefit of primary tumor surgery in this population.

Similar to our investigation, several retrospective studies found that primary tumor surgery has a favorable prognostic impact on metastatic patients with other malignancies, such as breast,[@b10-cmar-11-339]--[@b14-cmar-11-339] colorectal,[@b15-cmar-11-339]--[@b17-cmar-11-339] gastric[@b18-cmar-11-339]--[@b20-cmar-11-339] and renal cell cancer.[@b21-cmar-11-339] Lowering the tumor burden,[@b27-cmar-11-339],[@b28-cmar-11-339] reducing recirculating tumor cells,[@b29-cmar-11-339] decreasing the cytokines regulating tumor metastasis[@b30-cmar-11-339] and restoring immunomodulation by removing potential source of immunosuppression from the primary site could explain the beneficial effect of primary tumor surgery.[@b31-cmar-11-339] Considering the inherent selection biases in these studies and several controversial conclusions,[@b32-cmar-11-339] and the theory of increased angiogenesis and accelerated relapse associated with surgical wound,[@b33-cmar-11-339],[@b34-cmar-11-339] the definitive effect and mechanisms of primary tumor surgery in these cancers and melanoma remain to be further clarified.

As we know, the targeted therapies and immune checkpoint inhibitors have been playing an vital role in treatment of metastatic melanoma since the US Food and Drug Administration approved BRAF V600E-targeted therapy and anti-CTLA4 immunotherapy for this cohort of patients in the year 2011.[@b35-cmar-11-339] We were confused by the fact whether the observed survival advantage in the surgical group was partly due to the effect of the novel agents mentioned above. As SEER does not provide the information whether patients have received the above treatments, we analyzed the effect of primary tumor surgery in pre (before 2011) and post (after 2011) the immune/targeted therapy periods, respectively. Also, we found that the surgery group had longer survival than the non-surgery group in both periods. Meanwhile, the COX regression analysis adjusted by the variables including time showed that surgery was a significantly independent prognostic factor, suggesting that the effect of surgery on survival may not be influenced by the targeted or immune therapy. Additionally, the SEER does not provide usable information of radiation and chemical therapy, which makes the adjustment impossible for the use of these treatments. Nonetheless, it seems unlikely that the significant effects of primary tumor surgery are due solely to unadjusted confounding.

In addition, we found that the proportion of the patients who received metastasectomy was only 2.1%, which is much lower than that of patients receiving the primary tumor surgery. According to available evidence, metastasectomy was proved to be an effective treatment option with a benefit of OS for selected patients.[@b5-cmar-11-339] Although metastasectomy was also associated with better survival in this study, its effect on improving the survival of metastatic population may be limited by the low proportion of the suitable candidates,[@b4-cmar-11-339] which has been described by previous studies.[@b35-cmar-11-339] Given the situation that the numbers of patients who had undergone primary tumor surgery and metastasectomy differed widely and more information was unavailable, the patients' selection for these two surgical methods or combined application should be further studied in well-designed clinical trials.

It is important to consider our study in the context of its limitations. Firstly, a bias due to the imbalance of the surgery group compared with the non-surgery group cannot be completely excluded, considering other potential prognostic factors, such as performance status, gene mutation status, the time between diagnosis and excision of the primary tumor, insurance status and so on, were not available in SEER. Secondly, the "unknown" subgroups of some variables included in the analysis may incur biases. Thirdly, we were not able to evaluate the impact of primary tumor surgery on the quality of life of patients because the information on complications or adverse reactions after surgery is not available in the SEER database.

Conclusion
==========

Despite the limitations, this study reveals that primary tumor surgery significantly benefits both OS and MSS of patients with newly diagnosed metastatic melanoma. The results may fill in the gaps of the guidelines, but need to be validated by further prospective studies or trials.
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###### 

Baseline variables before and after propensity score matching

  Characteristics                  Unmatched cohort (n=8,341)   Matched cohort (n=1,476)                                                         
  -------------------------------- ---------------------------- -------------------------- ---------- --------- ------------ ------------ ------ -------
  Year of diagnosis                                                                        24.25      \<0.001                             0.03   0.870
   2004--2010                      3,000 (51.8)                 1,473 (57.7)                                    479 (64.9)   482 (65.3)          
   2011--2015                      2,787 (48.2)                 1,081 (42.3)                                    259 (35.1)   256 (34.7)          
  Sex                                                                                      0.00       0.996                               1.00   0.317
   Female                          1,801 (31.1)                 795 (31.1)                                      231 (31.3)   249 (33.7)          
   Male                            3,986 (68.9)                 1,759 (68.9)                                    507 (68.7)   489 (66.3)          
  Age at diagnosis (years)                                                                 17.50      0.001                               2.16   0.540
   ≤40                             314 (5.4)                    181 (7.1)                                       46 (6.2)     50 (6.8)            
   41--60                          1,647 (28.5)                 779 (30.5)                                      225 (30.5)   235 (31.8)          
   61--80                          2,806 (48.5)                 1,132 (44.3)                                    327 (44.3)   334 (45.3)          
   ≥81                             1,020 (17.6)                 462 (18.1)                                      140 (19.0)   119 (16.1)          
  Race                                                                                     4.77       0.312                               7.78   0.100
   White                           5,569 (96.2)                 2,464 (96.5)                                    705 (95.5)   717 (97.2)          
   Black                           89 (1.5)                     45 (1.8)                                        13 (1.8)     10 (1.4)            
   American Indian/Alaska Native   56 (1.0)                     19 (0.7)                                        12 (1.6)     4 (0.5)             
   Asian or Pacific Islander       59 (1.0)                     17 (0.7)                                        6 (0.8)      2 (0.3)             
   Unknown                         14 (0.2)                     9 (0.4)                                         2 (0.3)      5 (0.7)             
  Marital status                                                                           10.88      0.004                               7.46   0.024
   Unmarried                       2,160 (37.3)                 1,015 (39.7)                                    319 (43.2)   268 (36.3)          
   Married                         3,343 (57.8)                 1,385 (54.2)                                    379 (51.4)   428 (58.0)          
   Unknown                         284 (4.9)                    154 (6.0)                                       40 (5.4)     42 (5.7)            
  Primary site                                                                             4,389.20   \<0.001                             7.21   0.066
   Limbs                           290 (5.0)                    835 (32.7)                                      211 (28.6)   182 (24.7)          
   Trunk                           307 (5.3)                    812 (31.8)                                      218 (29.5)   196 (26.6)          
   Face/head/neck                  250 (4.3)                    678 (26.5)                                      160 (21.7)   185 (25.1)          
   Other                           4,940 (85.4)                 229 (9.0)                                       149 (20.2)   175 (23.7)          
  Histologic type                                                                          1,701.66   \<0.001                             0.25   0.969
   SSM                             27 (0.5)                     257 (10.1)                                      17 (2.3)     17 (2.3)            
   NM                              72 (1.2)                     569 (22.3)                                      44 (6.0)     41 (5.6)            
   SCM                             110 (1.9)                    64 (2.5)                                        13 (1.8)     15 (2.0)            
   Other/unknown                   5,578 (96.4)                 1,664 (65.2)                                    664 (90.0)   665 (90.1)          
  T stage                                                                                  4,095.13   \<0.001                             3.25   0.517
   T1                              73 (1.3)                     332 (13.0)                                      35 (4.7)     34 (4.6)            
   T2                              43 (0.7)                     265 (10.4)                                      34 (4.6)     26 (3.5)            
   T3                              51 (0.9)                     382 (15.0)                                      44 (6.0)     36 (4.9)            
   T4                              79 (1.4)                     789 (30.9)                                      56 (7.6)     69 (9.3)            
   Unknown                         5,541 (95.7)                 786 (30.8)                                      569 (77.1)   573 (77.6)          
  N stage                                                                                  1,460.02   \<0.001                             5.13   0.274
   N0                              891 (15.4)                   533 (20.9)                                      156 (21.1)   141 (19.1)          
   N1                              1,835 (31.7)                 1,048 (41.0)                                    289 (39.2)   272 (36.9)          
   N2                              85 (1.5)                     248 (9.7)                                       40 (5.4)     52 (7.0)            
   N3                              130 (2.2)                    389 (15.2)                                      62 (8.4)     80 (10.8)           
   Nx                              2,846 (49.2)                 336 (13.2)                                      191 (25.9)   193 (26.2)          
  M stage                                                                                  310.70     \<0.001                             2.73   0.256
   M1a                             570 (9.8)                    626 (24.5)                                      108 (14.6)   131 (17.8)          
   M1b/c                           3,932 (67.9)                 1,471 (57.6)                                    451 (61.1)   430 (58.3)          
   Mx                              1,285 (22.2)                 457 (17.9)                                      179 (24.3)   177 (24.0)          
  Ulceration                                                                               3,007.38   \<0.001                             0.11   0.947
   No                              676 (11.7)                   659 (25.8)                                      87 (11.8)    83 (11.2)           
   Yes                             125 (2.2)                    1,098 (43.0)                                    96 (13.0)    96 (13.0)           
  Unknown                          4,986 (86.2)                 797 (31.2)                                      555 (75.2)   559 (75.7)          
  Metastasectomy                                                                           3.80       0.051                               0.63   0.429
   No                              5,656 (97.7)                 2,513 (98.4)                                    727 (98.5)   723 (98.0)          
   Yes                             131 (2.3)                    41 (1.6)                                        11 (1.5)     15 (2.0)            

**Abbreviations:** NM, nodular melanoma; SCM, spindle cell melanoma; SSM, superficial spreading melanoma.

###### 

Multivariate analysis of prognostic factors for survival in the unmatched population

  Variables                  Category     OS        MSS                                                                                           
  -------------------------- ------------ --------- -------------- -------------- ------------------------------------------------ -------------- --------------
  Year of diagnosis          2011--2015   \<0.001   0.837          0.790--0.886   \<0.001                                          0.704          0.656--0.75
  Sex                        Male         \<0.001   1.128          1.067--1.193   \<0.001                                          1.151          1.076--1.231
  Age at diagnosis (years)   ≤40          \<0.001                                 \<0.001                                                         
  41--60                     \<0.001      1.229     1.091--1.385   0.002          1.220                                            1.075--1.384   
  61--80                     \<0.001      1.425     1.269--1.600   \<0.001        1.321                                            1.166--1.497   
  ≥81                        \<0.001      1.924     1.700--2.178   \<0.001        1.742                                            1.511--2.007   
  Marital status             Unmarried    \<0.001                                 \<0.001                                                         
  Married                    \<0.001      0.770     0.730--0.813   \<0.001        0.732                                            0.686--0.781   
  Unknown                    \<0.001      0.692     0.610--0.785   \<0.001        0.620                                            0.526--0.732   
  Primary site               Limbs        \<0.001                                 \<0.001                                                         
  Trunk                      0.036        1.110     1.007--1.223   0.123          1.098                                            0.975--1.237   
  Face/head/neck             0.196        0.933     0.840--1.036   0.068          0.882                                            0.770--1.009   
  Other                      0.020        0.888     0.803--0.981   0.007          0.847                                            0.750--0.957   
  Histologic type            SSM          0.001                                   0.001                                                           
  NM                         0.005        1.303     1.083--1.567   0.004          1.390                                            1.112--1.739   
  SCM                        0.662        0.946     0.737--1.214   0.704          0.942                                            0.691--1.284   
  Other/unknown              0.021        1.222     1.031--1.449   0.022          1.273                                            1.035--1.564   
  T stage                    T1           0.021                                   N/A[a](#tfn2-cmar-11-339){ref-type="table-fn"}                  
  T2                         0.529        1.060     0.884--1.272                                                                                  
  T3                         0.440        1.067     0.905--1.259                                                                                  
  T4                         0.005        1.230     1.063--1.423                                                                                  
  Unknown                    0.632        1.035     0.899--1.192                                                                                  
  N stage                    N0           \<0.001                                                                                                 
  N1                         0.001        1.139     1.052--1.233   0.001          1.179                                            1.068--1.302   
  N2                         0.924        1.007     0.865--1.174   0.876          0.985                                            0.814--1.192   
  N3                         \<0.001      1.337     1.182--1.511   \<0.001        1.453                                            1.256--1.681   
  Nx                         \<0.001      1.279     1.186--1.379   \<0.001        1.333                                            1.212--1.465   
  M stage                    M1a          \<0.001                                 \<0.001                                                         
  M1b/c                      \<0.001      2.191     2.013--2.383   \<0.001        2.559                                            2.294--2.854   
  Mx                         \<0.001      1.875     1.705--2.061   \<0.001        2.119                                            1.876--2.393   
  Primary tumor surgery      Yes          \<0.001   0.617          0.565--0.674   \<0.001                                          0.599          0.537--0.668
  Metastasectomy             Yes          \<0.001   0.466          0.381--0.570   \<0.001                                          0.434          0.341--0.553

**Note:**

This item is not included in the multivariable logistic regression.

**Abbreviations:** B, partial regression coefficients; Exp, exponential function; MSS, melanoma-specific survival; NM, nodular melanoma; OS, overall survival; SCM, spindle cell melanoma; SSM, superficial spreading melanoma.
